The unique monoclonal immunoglobulin, Pritoxaximab – formerly known as DXX00601 – shows significant potential within the therapy of severe hemolytic disease (TRALI). Created by the company, Pritoxaximab works by https://www.targetmol.com/compound/pritoxaximab